{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:29:30Z","timestamp":1791340170495,"version":"4.3.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"DOI":"10.7759\/cureus.65202","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T15:46:17Z","timestamp":1721749577000},"source":"Crossref","is-referenced-by-count":8,"title":["Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Majed  S","family":"Alqahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid F","family":"Alzibali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz Mahdi M","family":"Mahdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama Mohammed  A","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem Hafiz  A","family":"Harbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad Saad  M","family":"Alkhaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahrah Ali  A","family":"Alsayafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema  H","family":"Albisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtadha  H","family":"Buqurayn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meshal  M","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-021-00497-3","article-title":"Lipid-lowering drug therapy: critical approach for implementation in clinical practice","volume":"22","author":"Rossi M","year":"2022","unstructured":"Rossi M, Fabris E, Barbisan D, Massa L, Sinagra G. Lipid-lowering drug therapy: critical approach for implementation in clinical practice. Am J Cardiovasc Drugs. 2022, 22:141-55. 10.1007\/s40256-021-00497-3","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-04968-8","article-title":"The effects of the interaction between BMI and dyslipidemia on hypertension in adults","volume":"12","author":"Tang N","year":"2022","unstructured":"Tang N, Ma J, Tao R, et al.. The effects of the interaction between BMI and dyslipidemia on hypertension in adults. Sci Rep. 2022, 12:927. 10.1038\/s41598-022-04968-8","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.10.1066","article-title":"Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women","volume":"164","author":"Hu G","year":"2004","unstructured":"Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004, 164:1066-76. 10.1001\/archinte.164.10.1066","journal-title":"Arch Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-021-01612-8","article-title":"Triglyceride\/low-density-lipoprotein cholesterol ratio is the most valuable predictor for increased small, dense LDL in type 2 diabetes patients","volume":"21","author":"Ouchi G","year":"2022","unstructured":"Ouchi G, Komiya I, Taira S, Wakugami T, Ohya Y. Triglyceride\/low-density-lipoprotein cholesterol ratio is the most valuable predictor for increased small, dense LDL in type 2 diabetes patients. Lipids Health Dis. 2022, 21:4. 10.1186\/s12944-021-01612-8","journal-title":"Lipids Health Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/nu12041098","article-title":"Ubiquinol ameliorates endothelial dysfunction in subjects with mild-to-moderate dyslipidemia: a randomized clinical trial","volume":"12","author":"Sabbatinelli J","year":"2020","unstructured":"Sabbatinelli J, Orlando P, Galeazzi R, et al.. Ubiquinol ameliorates endothelial dysfunction in subjects with mild-to-moderate dyslipidemia: a randomized clinical trial. Nutrients. 2020, 12:1098. 10.3390\/nu12041098","journal-title":"Nutrients"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.03.004","article-title":"A paradigm shift in dyslipidemia management in primary care: a 12-month cohort study","volume":"44","author":"Hong JH","year":"2022","unstructured":"Hong JH, Jeon U, Shin WY, et al.. A paradigm shift in dyslipidemia management in primary care: a 12-month cohort study. Clin Ther. 2022, 44:698-709. 10.1016\/j.clinthera.2022.03.004","journal-title":"Clin Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2412373","article-title":"Landscape of statin as a cornerstone in atherosclerotic cardiovascular disease","volume":"24","author":"Yang C","year":"2023","unstructured":"Yang C, Wu Y-J, Qian J, Li JJ . Landscape of statin as a cornerstone in atherosclerotic cardiovascular disease. Rev Cardiovasc Med. 2023, 24:373. 10.31083\/j.rcm2412373","journal-title":"Rev Cardiovasc Med"},{"key":"ref8","unstructured":"Statins vs fibrates in dyslipidemia. (2023). Accessed. May 5, 2024: https:\/\/www.medscape.com\/viewarticle\/995550."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon CP","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al.. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015, 372:2387-97. 10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy","volume":"9","author":"Chaudhary R","year":"2017","unstructured":"Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: a new era of lipid lowering therapy. World J Cardiol. 2017, 9:76-91. 10.4330\/wjc.v9.i2.76","journal-title":"World J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0541-3","article-title":"Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review","volume":"16","author":"Oscarsson J","year":"2017","unstructured":"Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017, 16:149. 10.1186\/s12944-017-0541-3","journal-title":"Lipids Health Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042056","article-title":"The effects of antioxidants from natural products on obesity, dyslipidemia, diabetes and their molecular signaling mechanism","volume":"23","author":"Khutami C","year":"2022","unstructured":"Khutami C, Sumiwi SA, Khairul Ikram NK, Muchtaridi M. The effects of antioxidants from natural products on obesity, dyslipidemia, diabetes and their molecular signaling mechanism. Int J Mol Sci. 2022, 23:2056. 10.3390\/ijms23042056","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020786","article-title":"Metabolic syndrome: updates on pathophysiology and management in 2021","volume":"23","author":"Fahed G","year":"2022","unstructured":"Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022, 23:786. 10.3390\/ijms23020786","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031438","article-title":"Evaluation of oxidative stress biomarkers, pro-inflammatory cytokines, and histological changes in experimental hypertension, dyslipidemia, and type 1 diabetes mellitus","volume":"23","author":"Boarescu PM","year":"2022","unstructured":"Boarescu PM, Boarescu I, Pop RM, et al.. Evaluation of oxidative stress biomarkers, pro-inflammatory cytokines, and histological changes in experimental hypertension, dyslipidemia, and type 1 diabetes mellitus. Int J Mol Sci. 2022, 23:1438. 10.3390\/ijms23031438","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-022-02489-w","article-title":"Dyslipidemia and its associated factors among adult diabetes outpatients in West Shewa zone public hospitals, Ethiopia","volume":"22","author":"Abdissa D","year":"2022","unstructured":"Abdissa D, Hirpa D. Dyslipidemia and its associated factors among adult diabetes outpatients in West Shewa zone public hospitals, Ethiopia. BMC Cardiovasc Disord. 2022, 22:39. 10.1186\/s12872-022-02489-w","journal-title":"BMC Cardiovasc Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156624","article-title":"Sortilin drives hypertension by modulating sphingolipid\/ceramide homeostasis and by triggering oxidative stress","volume":"132","author":"Varzideh F","year":"2022","unstructured":"Varzideh F, Jankauskas SS, Kansakar U, Mone P, Gambardella J, Santulli G. Sortilin drives hypertension by modulating sphingolipid\/ceramide homeostasis and by triggering oxidative stress. J Clin Invest. 2022, 132:e156624. 10.1172\/JCI156624","journal-title":"J Clin Invest"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020673","article-title":"Pathophysiology of mild hypercortisolism: from the bench to the bedside","volume":"23","author":"Favero V","year":"2022","unstructured":"Favero V, Cremaschi A, Parazzoli C, et al.. Pathophysiology of mild hypercortisolism: from the bench to the bedside. Int J Mol Sci. 2022, 23:673. 10.3390\/ijms23020673","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.05.005","article-title":"Vasoreactivity of isolated aortic rings from dyslipidemic and insulin resistant inducible nitric oxide synthase knockout mice","volume":"855","author":"Pathak P","year":"2019","unstructured":"Pathak P, Kanshana JS, Kanuri B, Rebello SC, Aggarwal H, Jagavelu K, Dikshit M. Vasoreactivity of isolated aortic rings from dyslipidemic and insulin resistant inducible nitric oxide synthase knockout mice. Eur J Pharmacol. 2019, 855:90-7. 10.1016\/j.ejphar.2019.05.005","journal-title":"Eur J Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9080736","article-title":"Systemic insulin resistance and metabolic perturbations in chow fed inducible nitric oxide synthase knockout male mice: partial reversal by nitrite supplementation","volume":"9","author":"Aggarwal H","year":"2020","unstructured":"Aggarwal H, Pathak P, Singh P, Gayen JR, Jagavelu K, Dikshit M. Systemic insulin resistance and metabolic perturbations in chow fed inducible nitric oxide synthase knockout male mice: partial reversal by nitrite supplementation. Antioxidants (Basel). 2020, 9:736. 10.3390\/antiox9080736","journal-title":"Antioxidants (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2018.02.002","article-title":"Effects of long-term nitrate supplementation on carbohydrate metabolism, lipid profiles, oxidative stress, and inflammation in male obese type 2 diabetic rats","volume":"75","author":"Gheibi S","year":"2018","unstructured":"Gheibi S, Jeddi S, Carlstr\u00f6m M, Gholami H, Ghasemi A. Effects of long-term nitrate supplementation on carbohydrate metabolism, lipid profiles, oxidative stress, and inflammation in male obese type 2 diabetic rats. Nitric Oxide. 2018, 75:27-41. 10.1016\/j.niox.2018.02.002","journal-title":"Nitric Oxide"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19545-1","article-title":"Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels","volume":"8","author":"Kuno T","year":"2018","unstructured":"Kuno T, Hirayama-Kurogi M, Ito S, Ohtsuki S. Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels. Sci Rep. 2018, 8:1253. 10.1038\/s41598-018-19545-1","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05336-9","article-title":"Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism","volume":"9","author":"Zarrinpar A","year":"2018","unstructured":"Zarrinpar A, Chaix A, Xu ZZ, et al.. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. Nat Commun. 2018, 9:2872. 10.1038\/s41467-018-05336-9","journal-title":"Nat Commun"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-2096-8","article-title":"Metabolic signature of obesity-associated insulin resistance and type 2 diabetes","volume":"17","author":"Al-Sulaiti H","year":"2019","unstructured":"Al-Sulaiti H, Diboun I, Agha MV, et al.. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes. J Transl Med. 2019, 17:348. 10.1186\/s12967-019-2096-8","journal-title":"J Transl Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova B","year":"2012","unstructured":"Mihaylova B, Emberson J, Blackwell L, et al.. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012, 380:581-90. 10.1016\/S0140-6736(12)60367-5","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al.. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020, 41:111-88. 10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-015-0037-y","article-title":"Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey","volume":"14","author":"Krempf M","year":"2015","unstructured":"Krempf M, Simpson RJ Jr, Ramey DR, et al.. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Lipids Health Dis. 2015, 14:45. 10.1186\/s12944-015-0037-y","journal-title":"Lipids Health Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.56095\/eaj.v1i1.7","article-title":"The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs","volume":"1","author":"Ballantyne CM","year":"2022","unstructured":"Ballantyne CM, Catapano AL. The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs. Eur Atheroscler J. 2022, 1:2-13. 10.56095\/eaj.v1i1.7","journal-title":"Eur Atheroscler J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1677604","article-title":"PCSK9 inhibitors and cardiovascular outcomes","volume":"20","author":"Steffens D","year":"2020","unstructured":"Steffens D, Bramlage P, Scheeff C, Kasner M, Hassanein A, Friebel J, Rauch-Kr\u00f6hnert U. PCSK9 inhibitors and cardiovascular outcomes. Expert Opin Biol Ther. 2020, 20:35-47. 10.1080\/14712598.2020.1677604","journal-title":"Expert Opin Biol Ther"},{"key":"ref29","article-title":"Current indications, cost, and clinical use of anti-PCSK9 monoclonal antibodies","author":"Toklu B","year":"2016","unstructured":"Toklu B, Amirian J, Giugliano RP. Current indications, cost, and clinical use of anti-PCSK9 monoclonal antibodies. Am Coll Cardiol. 2016,","journal-title":"Am Coll Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68796-4","article-title":"Metabolomic analysis of primary human skeletal muscle cells during myogenic progression","volume":"10","author":"Kumar A","year":"2020","unstructured":"Kumar A, Kumar Y, Sevak JK, Kumar S, Kumar N, Gopinath SD. Metabolomic analysis of primary human skeletal muscle cells during myogenic progression. Sci Rep. 2020, 10:11824. 10.1038\/s41598-020-68796-4","journal-title":"Sci Rep"},{"key":"ref31","article-title":"Related factors of dyslipidemia among pre- and post-menopausal women in South Korea - based on the data of the sixth Korea National Health and Nutrition Examination survey(2013~2015)","volume":"8","author":"Sook KK","year":"2018","unstructured":"Sook KK. Related factors of dyslipidemia among pre- and post-menopausal women in South Korea - based on the data of the sixth Korea National Health and Nutrition Examination survey(2013~2015) . Asia-pacific Journal of Multimedia services convergent with Art, Humanities, and Sociology. 2018, 8:139-52.","journal-title":"Asia-pacific Journal of Multimedia services convergent with Art, Humanities, and Sociology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/2047487317691874","article-title":"Efficacy and safety of statins and exercise combination therapy compared to statin monotherapy in patients with dyslipidaemia: a systematic review and meta-analysis","volume":"24","author":"Gui YJ","year":"2017","unstructured":"Gui YJ, Liao CX, Liu Q, et al.. Efficacy and safety of statins and exercise combination therapy compared to statin monotherapy in patients with dyslipidaemia: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017, 24:907-16. 10.1177\/2047487317691874","journal-title":"Eur J Prev Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010466","article-title":"Statins-from fungi to pharmacy","volume":"25","author":"Sadowska A","year":"2023","unstructured":"Sadowska A, Osi\u0144ski P, Roztocka A, Kaczmarz-Chojnacka K, Zapora E, Sawicka D, Car H. Statins-from fungi to pharmacy. Int J Mol Sci. 2023, 25:466. 10.3390\/ijms25010466","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle A","year":"2017","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017, 120:229-43. 10.1161\/CIRCRESAHA.116.308537","journal-title":"Circ Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy293","article-title":"Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology","volume":"115","author":"Tu\u00f1\u00f3n J","year":"2019","unstructured":"Tu\u00f1\u00f3n J, Badim\u00f3n L, Bochaton-Piallat ML, et al.. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovasc Res. 2019, 115:10-9. 10.1093\/cvr\/cvy293","journal-title":"Cardiovasc Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jshs.2021.07.006","article-title":"Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: a systematic review and network meta-analysis","volume":"11","author":"Alvarez-Jimenez L","year":"2022","unstructured":"Alvarez-Jimenez L, Moreno-Caba\u00f1as A, Ramirez-Jimenez M, Morales-Palomo F, Ortega JF, Mora-Rodriguez R. Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: a systematic review and network meta-analysis. J Sport Health Sci. 2022, 11:567-77. 10.1016\/j.jshs.2021.07.006","journal-title":"J Sport Health Sci"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(19)30155-0","article-title":"Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data","volume":"4","author":"Zhu D","year":"2019","unstructured":"Zhu D, Chung HF, Dobson AJ, et al.. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019, 4:e553-64. 10.1016\/S2468-2667(19)30155-0","journal-title":"Lancet Public Health"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1394455","article-title":"Statin drug interactions and related adverse reactions: an update","volume":"17","author":"Bellosta S","year":"2018","unstructured":"Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018, 17:25-37. 10.1080\/14740338.2018.1394455","journal-title":"Expert Opin Drug Saf"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254907","article-title":"Impact of a family history of cardiovascular disease on prevalence, awareness, treatment, control of dyslipidemia, and healthy behaviors: findings from the Korea National Health and Nutrition Examination Survey","volume":"16","author":"Kim SJ","year":"2021","unstructured":"Kim SJ, Kwon OD, Lee EJ, Ock SM, Kim KS. Impact of a family history of cardiovascular disease on prevalence, awareness, treatment, control of dyslipidemia, and healthy behaviors: findings from the Korea National Health and Nutrition Examination Survey. PLoS One. 2021, 16:e0254907. 10.1371\/journal.pone.0254907","journal-title":"PLoS One"},{"key":"ref40","article-title":"Familial hypercholesterolemia: review of diagnosis, screening, and treatment","volume":"62","author":"Turgeon RD","year":"2016","unstructured":"Turgeon RD, Barry AR, Pearson GJ. Familial hypercholesterolemia: review of diagnosis, screening, and treatment. Can Fam Physician. 2016, 62:32-7.","journal-title":"Can Fam Physician"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/nu10081011","article-title":"Different risk for hypertension, diabetes, dyslipidemia, and hyperuricemia according to level of body mass index in Japanese and American subjects","volume":"10","author":"Kuwabara M","year":"2018","unstructured":"Kuwabara M, Kuwabara R, Niwa K, et al.. Different risk for hypertension, diabetes, dyslipidemia, and hyperuricemia according to level of body mass index in Japanese and American subjects. Nutrients. 2018, 10:1011. 10.3390\/nu10081011","journal-title":"Nutrients"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3987065","article-title":"Comparative lipid-lowering\/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials","volume":"2020","author":"Zhang X","year":"2020","unstructured":"Zhang X, Xing L, Jia X, et al.. Comparative lipid-lowering\/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials. Cardiovasc Ther. 2020, 2020:3987065. 10.1155\/2020\/3987065","journal-title":"Cardiovasc Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2020.1801634","article-title":"An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins","volume":"16","author":"Hirota T","year":"2020","unstructured":"Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 2020, 16:809-22. 10.1080\/17425255.2020.1801634","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20671","article-title":"Statins and hepatotoxicity: focus on patients with fatty liver","volume":"41","author":"Chalasani N","year":"2005","unstructured":"Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005, 41:690-5. 10.1002\/hep.20671","journal-title":"Hepatology"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028310","article-title":"High-intensity statin reduces the risk of mortality among chronic liver disease patients with atherosclerotic cardiovascular disease: a population-based cohort study","volume":"12","author":"Bea S","year":"2023","unstructured":"Bea S, Oh IS, Kim JH, Sinn DH, Chang Y, Ryu S, Shin JY. High-intensity statin reduces the risk of mortality among chronic liver disease patients with atherosclerotic cardiovascular disease: a population-based cohort study. J Am Heart Assoc. 2023, 12:e028310. 10.1161\/JAHA.122.028310","journal-title":"J Am Heart Assoc"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.03.031","article-title":"Prevalence and factors associated with statin use among patients with nonalcoholic fatty liver disease in the TARGET-NASH study","volume":"20","author":"Thomson MJ","year":"2022","unstructured":"Thomson MJ, Serper M, Khungar V, et al.. Prevalence and factors associated with statin use among patients with nonalcoholic fatty liver disease in the TARGET-NASH study. Clin Gastroenterol Hepatol. 2022, 20:458-460.e4. 10.1016\/j.cgh.2021.03.031","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1159\/000330355","article-title":"The role of statins in chronic kidney disease","volume":"34","author":"Kalaitzidis RG","year":"2011","unstructured":"Kalaitzidis RG, Elisaf MS. The role of statins in chronic kidney disease. Am J Nephrol. 2011, 34:195-202. 10.1159\/000330355","journal-title":"Am J Nephrol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53064-x","article-title":"Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis","volume":"9","author":"Esmeijer K","year":"2019","unstructured":"Esmeijer K, Dekkers OM, de Fijter JW, Dekker FW, Hoogeveen EK. Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Sci Rep. 2019, 9:16632. 10.1038\/s41598-019-53064-x","journal-title":"Sci Rep"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000798992.09378.14","article-title":"Statins no longer contraindicated in pregnancy","volume":"121","author":"Aschenbrenner DS","year":"2021","unstructured":"Aschenbrenner DS. Statins no longer contraindicated in pregnancy. Am J Nurs. 2021, 121:22. 10.1097\/01.NAJ.0000798992.09378.14","journal-title":"Am J Nurs"},{"key":"ref50","article-title":"Rosuvastatin","year":"2006","unstructured":"Rosuvastatin. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development, Bethesda, MD; 2006."},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling J","year":"2016","unstructured":"Besseling J, Hovingh GK, Huijgen R, Kastelein JJ, Hutten BA. Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. J Am Coll Cardiol. 2016, 68:252-60. 10.1016\/j.jacc.2016.04.054","journal-title":"J Am Coll Cardiol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-023-00594-5","article-title":"Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention","volume":"23","author":"Michaeli DT","year":"2023","unstructured":"Michaeli DT, Michaeli JC, Albers S, Boch T, Michaeli T. Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention. Am J Cardiovasc Drugs. 2023, 23:477-95. 10.1007\/s40256-023-00594-5","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor A","year":"2009","unstructured":"Pandor A, Ara RM, Tumur I, et al.. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009, 265:568-80. 10.1111\/j.1365-2796.2008.02062.x","journal-title":"J Intern Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990314","article-title":"Ezetimibe therapy for dyslipidemia: an update","volume":"19","author":"Katsiki N","year":"2013","unstructured":"Katsiki N, Theocharidou E, Karagiannis A, Athyros VG, Mikhailidis DP. Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des. 2013, 19:3107-14. 10.2174\/13816128113199990314","journal-title":"Curr Pharm Des"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S332352","article-title":"Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: current insights","volume":"16","author":"Chilbert MR","year":"2022","unstructured":"Chilbert MR, VanDuyn D, Salah S, Clark CM, Ma Q. Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: current insights. Drug Des Devel Ther. 2022, 16:2177-86. 10.2147\/DDDT.S332352","journal-title":"Drug Des Devel Ther"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-020-00421-1","article-title":"Rosuvastatin\/ezetimibe: a review in hypercholesterolemia","volume":"20","author":"Lamb YN","year":"2020","unstructured":"Lamb YN. Rosuvastatin\/ezetimibe: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2020, 20:381-92. 10.1007\/s40256-020-00421-1","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-15-1-32","article-title":"Poststatin lipid therapeutics: a review","volume":"15","author":"Jia X","year":"2019","unstructured":"Jia X, Lorenz P, Ballantyne CM. Poststatin lipid therapeutics: a review. Methodist Debakey Cardiovasc J. 2019, 15:32-8. 10.14797\/mdcj-15-1-32","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref58","unstructured":"Ezetimibe tablet. (2021 ). Accessed. June 4, 2024: https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=206d702c-b09a-4555-972b-6555d6d6d6e6."},{"key":"ref59","article-title":"Ezetimibe","author":"Sizar O","year":"2024","unstructured":"Sizar O, Nassereddin A, Talati R. Ezetimibe. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref60","article-title":"Ezetimibe","year":"2012","unstructured":"Ezetimibe. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2012."},{"key":"ref61","unstructured":"Praluent. (2024). Accessed. May 5, 2024: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/praluent.."},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29140","article-title":"A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease","volume":"14","author":"Igweonu-Nwakile EO","year":"2022","unstructured":"Igweonu-Nwakile EO, Ali S, Paul S, et al.. A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease. Cureus. 2022, 14:e29140. 10.7759\/cureus.29140","journal-title":"Cureus"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04282.x","article-title":"The clofibrate saga: a retrospective commentary","volume":"74","author":"Oliver M","year":"2012","unstructured":"Oliver M. The clofibrate saga: a retrospective commentary. Br J Clin Pharmacol. 2012, 74:907-10. 10.1111\/j.1365-2125.2012.04282.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1080\/10790268.2019.1581694","article-title":"Fenofibrate therapy to lower serum triglyceride concentrations in persons with spinal cord injury: a preliminary analysis of its safety profile","volume":"43","author":"La Fountaine MF","year":"2020","unstructured":"La Fountaine MF, Cirnigliaro CM, Hobson JC, Lombard AT, Specht AF, Dyson-Hudson TA, Bauman WA. Fenofibrate therapy to lower serum triglyceride concentrations in persons with spinal cord injury: a preliminary analysis of its safety profile. J Spinal Cord Med. 2020, 43:704-9. 10.1080\/10790268.2019.1581694","journal-title":"J Spinal Cord Med"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/nu12041032","article-title":"Dietary supplementation with curcumin reduce circulating levels of glycogen synthase kinase-3\u03b2 and islet amyloid polypeptide in adults with high risk of type 2 diabetes and Alzheimer\u2019s disease","volume":"12","author":"Thota RN","year":"2020","unstructured":"Thota RN, Rosato JI, Dias CB, Burrows TL, Martins RN, Garg ML. Dietary supplementation with curcumin reduce circulating levels of glycogen synthase kinase-3\u03b2 and islet amyloid polypeptide in adults with high risk of type 2 diabetes and Alzheimer\u2019s disease. Nutrients. 2020, 12:1032. 10.3390\/nu12041032","journal-title":"Nutrients"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S247351","article-title":"Comparative effects of curcumin versus nano-curcumin on insulin resistance, serum levels of apelin and lipid profile in type 2 diabetic rats","volume":"13","author":"Shamsi-Goushki A","year":"2020","unstructured":"Shamsi-Goushki A, Mortazavi Z, Mirshekar MA, Mohammadi M, Moradi-Kor N, Jafari-Maskouni S, Shahraki M. Comparative effects of curcumin versus nano-curcumin on insulin resistance, serum levels of apelin and lipid profile in type 2 diabetic rats. Diabetes Metab Syndr Obes. 2020, 13:2337-46. 10.2147\/DMSO.S247351","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmac072","article-title":"An investigative review for pharmaceutical analysis of fenofibrate","volume":"61","author":"Saha M","year":"2023","unstructured":"Saha M, Dhiman S, Gupta GD, Asati V. An investigative review for pharmaceutical analysis of fenofibrate. J Chromatogr Sci. 2023, 61:494-504. 10.1093\/chromsci\/bmac072","journal-title":"J Chromatogr Sci"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-016-0286-4","article-title":"The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia","volume":"15","author":"Backes J","year":"2016","unstructured":"Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis. 2016, 15:118. 10.1186\/s12944-016-0286-4","journal-title":"Lipids Health Dis"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.41898","article-title":"Effectiveness of a novel \u03c9-3 krill oil agent in patients with severe hypertriglyceridemia: a randomized clinical trial","volume":"5","author":"Mozaffarian D","year":"2022","unstructured":"Mozaffarian D, Maki KC, Bays HE, et al.. Effectiveness of a novel \u03c9-3 krill oil agent in patients with severe hypertriglyceridemia: a randomized clinical trial. JAMA Netw Open. 2022, 5:e2141898. 10.1001\/jamanetworkopen.2021.41898","journal-title":"JAMA Netw Open"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.1039056","article-title":"The effect of omega-3 fatty acids and its combination with statins on lipid profile in patients with hypertriglyceridemia: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Yang Y","year":"2022","unstructured":"Yang Y, Deng W, Wang Y, et al.. The effect of omega-3 fatty acids and its combination with statins on lipid profile in patients with hypertriglyceridemia: a systematic review and meta-analysis of randomized controlled trials. Front Nutr. 2022, 9:1039056. 10.3389\/fnut.2022.1039056","journal-title":"Front Nutr"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2015.01.001","article-title":"Familial hypercholesterolemia","volume":"33","author":"Bouhairie VE","year":"2015","unstructured":"Bouhairie VE, Goldberg AC. Familial hypercholesterolemia. Cardiol Clin. 2015, 33:169-79. 10.1016\/j.ccl.2015.01.001","journal-title":"Cardiol Clin"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091078","article-title":"Treatment of dyslipidaemia in children","volume":"9","author":"Fiorentino R","year":"2021","unstructured":"Fiorentino R, Chiarelli F. Treatment of dyslipidaemia in children. Biomedicines. 2021, 9:1078. 10.3390\/biomedicines9091078","journal-title":"Biomedicines"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-014-6516-y","article-title":"Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus","volume":"28","author":"Rosenson RS","year":"2014","unstructured":"Rosenson RS, Rigby SP, Jones MR, Chou HS. Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus. Cardiovasc Drugs Ther. 2014, 28:229-36. 10.1007\/s10557-014-6516-y","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1358759","article-title":"The glucose and lipid effects of colesevelam as monotherapy in drug-na\u00efve type 2 diabetes","volume":"46","author":"Rosenstock J","year":"2014","unstructured":"Rosenstock J, Rigby SP, Ford DM, Tao B, Chou HS. The glucose and lipid effects of colesevelam as monotherapy in drug-na\u00efve type 2 diabetes. Horm Metab Res. 2014, 46:348-53. 10.1055\/s-0033-1358759","journal-title":"Horm Metab Res"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2016.07.006","article-title":"Familial hypercholesterolemia: advances in recognition and therapy","volume":"59","author":"Cartier JL","year":"2016","unstructured":"Cartier JL, Goldberg AC. Familial hypercholesterolemia: advances in recognition and therapy. Prog Cardiovasc Dis. 2016, 59:125-34. 10.1016\/j.pcad.2016.07.006","journal-title":"Prog Cardiovasc Dis"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101342","article-title":"Lipid lowering therapy: an era beyond statins","volume":"47","author":"Abdul-Rahman T","year":"2022","unstructured":"Abdul-Rahman T, Bukhari SM, Herrera EC, et al.. Lipid lowering therapy: an era beyond statins. Curr Probl Cardiol. 2022, 47:101342. 10.1016\/j.cpcardiol.2022.101342","journal-title":"Curr Probl Cardiol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd10050195","article-title":"Bempedoic acid: an emerging therapy for uncontrolled low-density lipoprotein (LDL) cholesterol","volume":"10","author":"Pradhan A","year":"2023","unstructured":"Pradhan A, Bhandari M, Vishwakarma P, Singh A, Perrone MA, Sethi R. Bempedoic acid: an emerging therapy for uncontrolled low-density lipoprotein (LDL) cholesterol. J Cardiovasc Dev Dis. 2023, 10:195. 10.3390\/jcdd10050195","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000706","article-title":"New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia","volume":"29","author":"Pirillo A","year":"2022","unstructured":"Pirillo A, Catapano AL. New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes. 2022, 29:161-6. 10.1097\/MED.0000000000000706","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone NJ","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al.. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014, 63:2889-934. 10.1016\/j.jacc.2013.11.002","journal-title":"J Am Coll Cardiol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.519","article-title":"2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents","volume":"68","author":"Lloyd-Jones DM","year":"2016","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, et al.. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2016, 68:92-125. 10.1016\/j.jacc.2016.03.519","journal-title":"J Am Coll Cardiol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine MS","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al.. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017, 376:1713-22. 10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia-full report","volume":"8","author":"Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members","year":"2014","unstructured":"Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia-full report. J Clin Lipidol. 2014, 8:29-60. 10.1016\/j.jacl.2013.12.005","journal-title":"J Clin Lipidol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2022.07.009","article-title":"Guidelines for dyslipidemia management in India: a review of the current scenario and gaps in research","volume":"74","author":"Misra S","year":"2022","unstructured":"Misra S, Lyngdoh T, Mulchandani R. Guidelines for dyslipidemia management in India: a review of the current scenario and gaps in research. Indian Heart J. 2022, 74:341-50. 10.1016\/j.ihj.2022.07.009","journal-title":"Indian Heart J"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary","volume":"8","author":"Jacobson TA","year":"2014","unstructured":"Jacobson TA, Ito MK, Maki KC, et al.. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014, 8:473-88. 10.1016\/j.jacl.2014.07.007","journal-title":"J Clin Lipidol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.3390\/ph15121573","article-title":"Targeted treatment against lipoprotein (a): the coming breakthrough in lipid lowering therapy","volume":"15","author":"Sosnowska B","year":"2022","unstructured":"Sosnowska B, Surma S, Banach M. Targeted treatment against lipoprotein (a): the coming breakthrough in lipid lowering therapy. Pharmaceuticals (Basel). 2022, 15:1573. 10.3390\/ph15121573","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab841","article-title":"The dawn of a new era of targeted lipid-lowering therapies","volume":"43","author":"Tokg\u00f6zo\u011flu L","year":"2022","unstructured":"Tokg\u00f6zo\u011flu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J. 2022, 43:3198-208. 10.1093\/eurheartj\/ehab841","journal-title":"Eur Heart J"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger C","year":"2017","unstructured":"Landlinger C, Pouwer MG, Juno C, et al.. The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Heart J. 2017, 38:2499-507. 10.1093\/eurheartj\/ehx260","journal-title":"Eur Heart J"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-022-00698-6","article-title":"Recent advances in modulation of cardiovascular diseases by the gut microbiota","volume":"36","author":"Masenga SK","year":"2022","unstructured":"Masenga SK, Hamooya B, Hangoma J, et al.. Recent advances in modulation of cardiovascular diseases by the gut microbiota. J Hum Hypertens. 2022, 36:952-9. 10.1038\/s41371-022-00698-6","journal-title":"J Hum Hypertens"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.2217\/clp.10.73","article-title":"Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies","volume":"5","author":"Kassim SH","year":"2010","unstructured":"Kassim SH, Wilson JM, Rader DJ. Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. Clin Lipidol. 2010, 5:793-809. 10.2217\/clp.10.73","journal-title":"Clin Lipidol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/259443-lipid-lowering-medications-for-managing-dyslipidemia-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T15:46:24Z","timestamp":1721749584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/259443-lipid-lowering-medications-for-managing-dyslipidemia-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":89,"URL":"https:\/\/doi.org\/10.7759\/cureus.65202","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}